ArticleJAMA network open2026
Adolescent Cannabis Use After Cannabis Legalization and the COVID-19 Pandemic.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Understanding how cannabis legalization and large-scale societal disruptions influence adolescent cannabis use is important, as early use is associated with adverse health and educational outcomes. California has the largest regulated cannabis market in the US and provides a unique context to study how major policy and societal shifts are associated with adolescent cannabis use. Objective: To examine how rates of adolescent cannabis use in California changed after recreational cannabis legalization (RCL) and the COVID-19 pandemic. Design, Setting, and Participants: This population-based time-series cross-sectional study included adolescents aged 13 to 17 years in a large, integrated health care delivery system in California who were universally screened for cannabis use during standard pediatric care from January 2011 to December 2024. Data were analyzed from March to September 2025. Exposures: California state RCL passage (November 9, 2016), which reduced penalties for underage possession of cannabis; implementation of legal sales of cannabis for adults (January 1, 2018); and the COVID-19 pandemic (March 19, 2020). Main Outcomes and Measures: Any cannabis use in the past-year, self-reported based on universal screening at standard pediatric well-child visits. Interrupted time series analyses were fit using Poisson regression, standardized for sociodemographic characteristics of the adolescent Kaiser Permanente Northern California population. Results: The study included 1 308 655 screening questionnaires completed over the 14-year study period (mean [SD] 7789 [3673] adolescent screenings per month), with a mean (SD) age of 15.0 (1.4) years at screening and 666 881 (51.0%) questionnaires from female participants. Before RCL passage, the mean rate of adolescent cannabis use was decreasing, from 10.39% (95% CI, 9.96%-10.82%) in January 2011 to 6.83% (95% CI, 6.54%-7.14%) in October 2016 (annual trend rate ratio [RR], 0.93 [95% CI, 0.92-0.94] per year). Rates started increasing at the time of RCL passage (slope change RR, 1.19 [95% CI, 1.06-1.35]), and rates continued to increase after implementation of legal retail sales (annual trend RR, 1.06 [95% CI, 1.02-1.11] per year). After the COVID-19 pandemic began, rates of adolescent cannabis use decreased substantially (level change RR, 0.86 [95% CI, 0.76-0.97]; slope change RR, 0.80 [95% CI, 0.70-0.91]). Rates of adolescent cannabis use continued to decrease slightly in the years after COVID-19, reaching a mean of 6.45% (95% CI, 6.15%-6.77%) in December 2024 (annual trend RR, 0.98 [95% CI, 0.96-0.997] per year). Conclusions and Relevance: In this large, retrospective cross-sectional study, adolescent cannabis use increased following RCL and decreased following the COVID-19 pandemic, returning to prelegalization rates by 2024. These results have important implications for clinicians and policymakers and could help estimate future changes in adolescent cannabis use in response to broad policy changes and societal shifts and inform more effective prevention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.